Search

WX-UK1

Independent studies show that administration of Wx-UK1 resulted in a decrease of tumor cell invasion, suggesting its efficacy as a an adjuvant antimetastatic therapy of carcinomas. … WX-UK1 is a 3-amidinophenylalanine-based non-cytotoxic small molecule that belongs to a new class of drugs.

KOS-2187

KOS-2187, a novel erythromycin-based motilin agonist, or motilide, as a clinical candidate for the treatment of gastrointestinal motility disorders such as gastroparesis and gastroesophageal reflux disease

Alfaxalone

Alfaxalone, also known as alphaxalone or alphaxolone, is a neuroactive steroid and general anaesthetic. … Along with alfadolone, it is also one of the constituents of anesthetic drug mixture althesin.

Betazole

A histamine H2 agonist used clinically to test gastric secretory function.

Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen

Elotuzumab

Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. … Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration.

Eprodisate

Eprodisate slows the decline of renal function in AA amyloidosis.

Cetuximab sarotalocan

Cetuximab sarotalocan is under investigation in clinical trial NCT03769506 (ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Altropane I-123

Altropane I-123 is under investigation in clinical trial NCT01950468 (A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the

Deferitazole

Deferitazole is an iron chelator. … It has been used in trials studying the treatment and basic science of Beta-thalassemia, Hepatic Impairment, Impaired Renal Function, Transfusional Iron Overload, and Iron Overload Due to Repeated Red